Podcast Index
Parcourez les podcasts par catégorie, ouvrez les épisodes récents et téléchargez l’audio pour l’écouter hors ligne.
BioCentury This Week
BioCentury
Public Relations Stories and Strategies
Stories and Strategies https://storiesandstrategies.ca/
Ecosofie: Succesvol samenleven
Marnix Kluiters
The Art of Growth
Joel Hubbard and Jim Zartman
3 Takeaways™
Lynn Thoman
Driven by Data: The Podcast
Orbition Group
Clinician to CEO : Export Your Medical Device With Confidence By Overcoming Go To Market Roadblocks For Medtech Growth
Hakeem Adebiyi
Marketing Square : Les secrets Growth Marketing ⚡️
Caroline Mignaux
FELIX PREHN DAILY MARKET NEWS By Goat Academy
Felix Prehn
Grands Leaders, les leçons de l'Histoire
Radio Classique
Sold Out Offers
Ceels Lockley | Offer Strategy Expert
Smarter Online Business - Tech, Tools & Truths for Websites that Sell
Carrie Saunders
Pharma and BioTech Daily
Pharma and BioTech News
Retail Daily Minute
Omni Talk Retail
Digimasters Shorts
Adam Nagus, Carly Wilson
Salud Financiera
Luis Ángel Hernández
Los mejores resúmenes de libros de StoryShots 📚
StoryShots
Organizing for Beautiful Living: Home Organizing Tips, Sustainable Organizing Tips, Decluttering Tips, and Time Management Tips for Working Moms and Busy Moms
Zeenat Siman Professional Organizer
Show Up and Be Heard
Becci McEvoy
The Responsible Marketing Podcast
Jo Long
Lead with Confidence
JP Warren
Sagrada Ambición con Nayla Norryh
Nayla Norryh
Next Level Leaders with Dr. Joseph Walker, III
Charisma Podcast Network
Crypto News Today | 2 Min News | The Daily News Now!
The Daily News Now!
Meditación del Día
Radio Ebenezer RD
Radio Advisory
Advisory Board
Wade Keller Pro Wrestling Post-shows
Pro Wrestling Torch
Convo By Design®
Josh Cooperman
The Professional Artist Podcast: Art Business Transformations
The Professional Artist Association
Tony Robbins Podcast Daily
Tony
WW – William Waack
CNN Brasil
JIJI news for English Learners-時事通信英語学習ニュース‐
時事通信社
Face à Lechypre
BFM Business
L'édito éco
Europe 1
Good Morning Mercati
Michele Seghizzi
L'angle éco de François Lenglet
RTL
Der Praxis-Podcast zu Liberating Structures
Caterina Reinker, Karin Wächtler, Christian Weinert, Anja Kässner
Business
BioCentury
New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts re...
AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the takeo...
Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $...
Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too.From AI to NAMs to starting a Phase I trial in the U.S., BioCentury’s 3rd Grand Round...
FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdi...
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data...
At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field’s approach to t...
Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin disc...
China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s analysts, along with special guests Detlev Mennerich, head of Boehringer I...
Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commissioner shifting the question from whether he will be fired to when. On the lates...
UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T cell engager companies. On the latest BioCe...
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make ...
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-i...
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASD...
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On the latest BioCentury This Week podcast, ...
Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt biotech’s recovery? On the latest BioCentur...
Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed to de-risk assets. The new momentum from Asia, in particular China, has added a f...
A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podcast, BioCentury’s Paul Bonanos assesses last week’s deals by Merck, which is lay...
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how the company has built...
Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to debut on NASDAQ — but will geopolitical tensions and war in the Middle East scut...
Remplissez le formulaire ci-dessous. Veillez à sélectionner à la fois Pays et Genres.
Envoyez-nous un message ci-dessous. Nous vous répondrons dans les 24 heures.